EARS Stock News: Auris Medical Holding Ltd nearly quintuples on promising coronavirus treatment
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ: EARS has leaped by 370% on Tuesday following promising news.
- Auris Medical Holding reported that its nasal spray could protect against coronavirus.
- A downside correction may make it a buying opportunity.
Investors will likely be all-ears to hear about a coronavirus treatment which is not invasive – Auris Medical Holding Ltd (NASDAQ: EARS) has jumped from $1.11 to close at $5.23 after hitting a high of $6.60 at one point – nearly a sixfold leap – before closing at "only" a 370% gain, nearly quintupling.
With all the buzz about COVID-19 vaccines, markets seem to have forgotten about treatments – and especially prevention. Auris' AM-301 solution is a nasal spray that may protect against pathogens and also allergens that travel via aerosols.
The Zug, Switzerland-based firm has shared results from an in-vitro test, a stage before testing it on animals or humans. Nevertheless, the tests have shown a reduction of the virus by up to 90%, similar to the efficacy rates of the Pfizer/BioNTech and Moderna vaccines.
While the UK gave its green light to Pfizer's jabs, it may take some time until they can be distributed and administered. In the meantime, cheap means of prevention can help in stopping the spread of the disease that grips the world.
EARS stock forecast
NASDAQ: EARS is falling by around 20% in Wednesday's premarket trading, a much-needed correction after the whopping surge. For traders, the question is – will Auris stocks resume their gains? Even if covid disappears by the end of 2021, the company is now on the radar of investors. Allergies are unlikely to go away anytime soon, and nor are other issues that the company addresses.
The small pharma firm – worth a minuscule $37 million – in developing a drug called Sonsuvi which is used to treat sudden deafness. Sonsuvi has already reached Phase 3 trials and may be ready for markets next year.
All in all, there is room for some upside after the recent correction.
- NASDAQ: EARS has leaped by 370% on Tuesday following promising news.
- Auris Medical Holding reported that its nasal spray could protect against coronavirus.
- A downside correction may make it a buying opportunity.
Investors will likely be all-ears to hear about a coronavirus treatment which is not invasive – Auris Medical Holding Ltd (NASDAQ: EARS) has jumped from $1.11 to close at $5.23 after hitting a high of $6.60 at one point – nearly a sixfold leap – before closing at "only" a 370% gain, nearly quintupling.
With all the buzz about COVID-19 vaccines, markets seem to have forgotten about treatments – and especially prevention. Auris' AM-301 solution is a nasal spray that may protect against pathogens and also allergens that travel via aerosols.
The Zug, Switzerland-based firm has shared results from an in-vitro test, a stage before testing it on animals or humans. Nevertheless, the tests have shown a reduction of the virus by up to 90%, similar to the efficacy rates of the Pfizer/BioNTech and Moderna vaccines.
While the UK gave its green light to Pfizer's jabs, it may take some time until they can be distributed and administered. In the meantime, cheap means of prevention can help in stopping the spread of the disease that grips the world.
EARS stock forecast
NASDAQ: EARS is falling by around 20% in Wednesday's premarket trading, a much-needed correction after the whopping surge. For traders, the question is – will Auris stocks resume their gains? Even if covid disappears by the end of 2021, the company is now on the radar of investors. Allergies are unlikely to go away anytime soon, and nor are other issues that the company addresses.
The small pharma firm – worth a minuscule $37 million – in developing a drug called Sonsuvi which is used to treat sudden deafness. Sonsuvi has already reached Phase 3 trials and may be ready for markets next year.
All in all, there is room for some upside after the recent correction.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.